ArriVent

What ArriVent does

ArriVent BioPharma is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania, with collaboration sites in Gaithersburg, Maryland and Burlingame, California. The company trades on NASDAQ under the ticker AVBP. ArriVent identifies, in-licenses, and develops differentiated oncology medicines from partners in China, Europe, South Korea, and Japan, focusing on indications with high unmet medical need, particularly in EGFR-mutant non-small cell lung cancer (NSCLC). Its lead asset, firmonertinib, is an oral, highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical EGFR mutations as well as exon 20 insertion and PACC mutations; it is approved in China for classical EGFR-mutant NSCLC and is in global Phase 3 development (FURVENT and ALPACCA trials). The pipeline is expanding into antibody-drug conjugates through partnerships with Aarvik Therapeutics (ARR-002, a dual-target MUC16/NaPi2b ADC), Lepu Biopharma (ARR-217, a CDH17 ADC), and Alphamab Oncology (ARR-421 and ARR-173), alongside a clinical combination study with InnoCare's SHP2 inhibitor.

ArriVent's business model is the in-licensing and global clinical development of externally discovered oncology assets, with future revenue dependent on regulatory approval and commercialization of firmonertinib and subsequent pipeline candidates. The company is pre-revenue and currently funds operations through equity capital and debt; as of December 2025 it reported $312.8 million in cash supplemented by a $75 million undrawn credit facility, and in May 2026 completed a $250 million financing, extending runway into the second half of 2027. R&D expense was $153.4 million in FY2025, and the firm reported a $166.3 million net loss for the year.

Go-to-market preparation is underway: the company is building a commercial organization under Chief Commercial Officer Brent Rice, with Field Director Medical Affairs roles engaging oncologists and key opinion leaders at academic and community oncology centers. The company has secured FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib and FDA IND clearance for ARR-002, materially de-risking the regulatory pathway for its first two programs. The company was founded by Bing Yao (CEO, formerly CEO of Viela Bio) and Stuart Lutzker (President of R&D, formerly VP at Genentech), with senior leadership drawn largely from Viela Bio, MedImmune/AstraZeneca, Genentech, and Amgen.

Name

ArriVent

Legal name

ArriVent BioPharma, Inc.

Website

https://arrivent.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

ArriVent BioPharma is a clinical-stage biopharmaceutical company that in-licenses and develops differentiated oncology therapies — led by the EGFR inhibitor firmonertinib and a pipeline of antibody-drug conjugates — for cancer patients with high unmet need, targeting global markets outside China.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Oncology drug development
• Targeted cancer therapies
• EGFR inhibitors
• Antibody drug conjugates
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Pennsylvania Furnace

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Pre-revenue clinical-stage company. Anticipates generating revenue from commercialization of firmonertinib and other pipeline candidates upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

ArriVent BioPharma is a clinical-stage biopharmaceutical company that identifies, in-licenses, develops, and plans to commercialize differentiated oncology medicines addressing unmet needs in difficult-to-treat cancers. Its lead candidate is firmonertinib, an oral, brain-penetrant EGFR inhibitor for NSCLC, supported by a pipeline of antibody-drug conjugates (ARR-002, ARR-217, ARR-421, ARR-173) targeting solid tumors in ovarian, endometrial, and gastrointestinal indications.

Product overview

ArriVent BioPharma is a clinical-stage biopharmaceutical company developing a pipeline of differentiated oncology therapeutics. The core product is firmonertinib, an oral EGFR inhibitor that has received FDA Breakthrough Therapy Designation for EGFR exon 20 insertion mutations and is in Phase 3 trials (FURVENT and ALPACCA). The pipeline includes multiple ADC candidates: ARR-002 (MUC16/NaPi2b dual-target, partnered with Aarvik Therapeutics), ARR-217 (CDH17 ADC from Lepu Biopharma), and ARR-421 and ARR-173 (from Alphamab Oncology partnership), targeting various solid tumors. The company operates through strategic partnerships to in-license promising drug candidates from global sources and advance them through development and potential commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Firmonertinib (formerly Furmonertinib) Oral, highly brain-penetrant, mutation-selective EGFR inhibitor active against both classical and uncommon EGFR mutations, including exon 20 insertion mutations and P-loop and aC-helix compressing (PACC) mutations, in development for non-small cell lung cancer (NSCLC). Approved in China for classical EGFR mutant NSCLC; FDA Breakthrough Therapy Designation granted for previously untreated EGFR exon 20 insertion NSCLC.
• ARR-002 (AV-P138-ADC) First-in-class dual-target MUC16/NaPi2b tetravalent antibody-drug conjugate (ADC) developed with Aarvik Therapeutics using the proprietary MUTTA and AQUALINK ADC platforms, with initial development focus on ovarian and endometrial cancers. Demonstrates superior anti-tumor activity compared to single-target ADCs and offers an improved therapeutic window.
• ARR-217 CDH17-targeting antibody-drug conjugate (ADC) in-licensed from Lepu Biopharma with a potential best-in-class profile, in development for gastrointestinal (GI) cancers. ArriVent holds exclusive global rights outside Greater China.
• ARR-421 Antibody-drug conjugate (ADC) candidate from the partnership with Alphamab Oncology, utilizing Alphamab's proprietary linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.
• ARR-173 Antibody-drug conjugate (ADC) candidate from the partnership with Alphamab Oncology, utilizing Alphamab's proprietary linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.

Quantifiable outcome

• Firmonertinib approved in China for classical EGFR mutant NSCLC by Allist Pharmaceuticals
• +4 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Aarvik TherapeuticscoreStrategic or Co-development Partner · 17 March 2026Collaboration to advance ARR-002 (AV-P138-ADC), a novel dual-target MUC16/NaPi2b tetravalent ADC for ovarian and endometrial cancers. Aarvik is responsible for discovery and preclinical validation using MUTTA™ and AQUALINK™ platforms; ArriVent leads global development and commercialization.
• Shanghai Allist PharmaceuticalscoreStrategic or Co-development PartnerLicensed firmonertinib from Allist for global development and commercialization outside China. Allist maintains China rights while ArriVent leads rest-of-world development. Firmonertinib is approved in China for classical EGFR mutant NSCLC under this partnership.
• Alphamab OncologyminorStrategic or Co-development PartnerPartnership for discovery, development, and commercialization of novel ADCs ARR-421 and ARR-173. Utilizes Alphamab's linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.
• Lepu BiopharmaminorStrategic or Co-development PartnerExclusive license agreement for ARR-217, a potential best-in-class CDH17 ADC targeting gastrointestinal cancers. ArriVent obtained exclusive global rights outside Greater China for development and commercialization.
• Beijing InnoCare Pharma Tech Co., Ltd.minorStrategic or Co-development PartnerClinical combination study of furmonertinib with ICP-189 (SHP2 inhibitor) targeting advanced or metastatic NSCLC patients with EGFR classical mutations.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• AstraZeneca: Owns Tagrisso (osimertinib), the dominant EGFR TKI in EGFR-mutant NSCLC, and is expanding EGFR-directed combos (e.g., with amivantamab). The primary entrenched competitor shaping firmonertinib's commercial opportunity.
• Takeda Pharmaceutical: Global oncology-focused biopharmaceutical company with multiple targeted oncology and ADC programs. Comparable at the platform/business-model level as a global developer/commercializer of differentiated cancer therapies.
• ImmunoGen (AbbVie): Pioneer in ADC drug development; its ovarian cancer ADC Elahere targets FRα, broadly comparable to ArriVent's ARR-002 in ovarian/endometrial cancers. Now part of AbbVie, giving it deeper commercial resources.
• Genentech (Roche): Roche/Genentech is a leading oncology franchise developer with established ADC and EGFR programs and is also where ArriVent's President R&D (Lutzker) led early oncology development. Highly relevant as a large-scale oncology incumbent and benchmarking reference.
• Mirati Therapeutics (Bristol-Myers Squibb): Developed Krazati (adagrasib), an EGFR-pathway / KRAS G12C inhibitor for NSCLC, before being acquired by BMS. Highly comparable commercial-stage oncology small-molecule competitor in the same indication space as firmonertinib.

Direct peers

• Cullinan Oncology: Clinical-stage oncology biotech advancing a pipeline that includes EGFR-directed therapies and ADCs targeting solid tumors. Direct overlap with ArriVent's lung cancer and ADC strategy.
• Black Diamond Therapeutics: Clinical-stage oncology biotech developing mutation-selective small molecules across EGFR and other oncogene targets in NSCLC. Like ArriVent, it focuses on differentiated, genetically defined patient subsets with limited treatment options.

Emerging players

• Erasca: Clinical-stage precision oncology biotech targeting the EGFR/RAS/MAPK pathway. Directly comparable mechanism-based approach to firmonertinib with similar stage and indication focus in NSCLC.
• Mersana Therapeutics: Clinical-stage biotech developing next-generation ADCs across solid tumors. Comparable to ArriVent's pipeline ADCs in modality (ADCs), scale (clinical-stage, ~few hundred employees) and target patient populations.

Regional players

• Allist Pharmaceuticals: Chinese partner that discovered firmonertinib and retains China rights where the drug is approved for classical EGFR mutant NSCLC. Operates in the same EGFR-mutant NSCLC space but solely in the Greater China market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ArriVent